R1 RCM Acquisition, Valuation, Funding & Investors

R1 RCM was acquired by TowerBrook Capital Partners for $8.9B in August 2024, a 3.9x multiple on $2.3B of revenue.

R1 RCM acquisition price

$8.9B

Acquired by TowerBrook Capital Partners · Aug 2024

R1 RCM revenue at acquisition

$2.3B

Last twelve months · Aug 2024

R1 RCM revenue multiple at acquisition

3.9x

EV/Revenue · Aug 2024

R1 RCM EBITDA multiple at acquisition

14.3x

EV/EBITDA · Aug 2024

R1 RCM Overview

About R1 RCM

R1 RCM is a Chicago-based revenue cycle management partner for hospitals and healthcare systems founded in 2003. Company uses proven operating model based on R1 Performance Stack designed to fit seamlessly into any healthcare organization's infrastructure, enhancing patient experience, improving provider economics, and providing revenue predictability regardless of payment models, patient engagement strategies, or care settings.


Founded

2003

HQ

United StatesChicago, IL

Website

r1rcm.com

Status

Acquired

Customer focus

B2B

Revenue model

Services, Subscription

Revenue

$2.3B (Aug 2024)

Valuation

$8.9B (acquired Aug 2024)

R1 RCM Acquisition

R1 RCM was acquired by TowerBrook Capital Partners for $8.9B on 1 August 2024.

The acquisition price implies a 3.9x revenue and 14.3x EBITDA multiple on $2.3B of revenue.

Before the acquisition R1 RCM had raised $200M across 1 funding round.

R1 RCM Inc. provides technology-driven revenue cycle management solutions, including automating revenue management, billing services, and intelligent automation using generative AI for healthcare providers and hospitals. The strategic rationale emphasizes TowerBrook's long-term partnership, shared vision for R1 as the leading automation platform in healthcare revenue management, and commitment to invest in core operations, customer performance, and expansion of intelligent automation capabilities. On August 1, 2024, R1 entered a definitive merger agreement for TowerBrook and CD&R to acquire all outstanding shares not already owned by TowerBrook at $14.30 per share in an all-cash transaction valuing the enterprise at $8.9 billion, a 29% premium to the unaffected closing price on February 23, 2024. The deal followed a special committee of independent directors evaluating alternatives after New Mountain Capital's February buyout proposal at nearly $6 billion valuation. Financed by committed debt and equity from the buyers, the acquisition closed on November 19, 2024, taking R1 private with shares delisted from Nasdaq and periodic SEC reporting suspended; Joe Flanagan was reappointed CEO to drive operational excellence. The transaction occurred amid competitive dynamics, including rival bids, and was supported by advisors like RBC Capital Markets for financing and Kirkland & Ellis for R1, highlighting confidence in R1's scale, technology, and market leadership in healthcare revenue cycle services.

R1 RCM acquisition details
AcquirerDateTypePriceEV/RevenueEV/EBITDA
  • TowerBrook Capital Partners
1 Aug 2024PE buyout$8.9B3.9x14.3x

R1 RCM Funding History

R1 RCM has raised a total of $200M across 1 funding round.

R1 RCM funding rounds

R1 RCM funding rounds
DateStageInvestorsRaisedDeal Summary
Dec 2015Undisclosed stageTowerBrook Capital Partners (lead); Ascension (lead)$200MAccretive Health, now R1 RCM, announced in December 2015 a USD 200 million investment from Ascension and TowerBrook Capital Partners in the form of convertible preferred stock, under an agreement dated 7 December 2015. The preferred stock was convertible into common stock at USD 2.50 per share, carried an 8.0 per cent annual dividend payable in kind for the first seven years and in cash thereafter, and represented approximately 44 per cent of the company on an as-converted basis, together with warrants over up to a further 60 million shares. Concurrently, Ascension and Accretive announced a long-term strategic partnership making Accretive the sole revenue cycle provider for Ascension. The transaction was expected to close in the first quarter of 2016. Accretive Health provides end-to-end revenue cycle management to hospitals and health systems from its Chicago headquarters. Covington & Burling advised Ascension on the investment.

Who has invested in R1 RCM?

2 investors have backed R1 RCM across its funding rounds, including TowerBrook Capital Partners and Ascension.

Lead investors include TowerBrook Capital Partners and Ascension.


R1 RCM Investors

Investors in R1 RCM by funding rounds participated
InvestorHQRoundsRoleFirst check

This data is available for Pro users. Sign up to see all 2 R1 RCM investors.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

Acquisitions by R1 RCM

R1 RCM has acquired 8 companies to date.

Last acquisition by R1 RCM was on August 18th 2026. R1 RCM acquired Humata Health for undisclosed valuation.


Latest Acquisitions by R1 RCM

Humata Health
Phare Health
Acclara Solutions
Cloudmed
Description
Humata Health is a New York-headquartered AI platform for prior authorizations launched in 2022. The company automates approvals between payers like UnitedHealthcare and providers using NLP on 10 million claims monthly. Its integration with Epic reduces processing from 10 days to 2 hours, serving 50 hospitals. Humata analyzes clinical notes for 95 percent accuracy in coverage decisions.
Phare Health streamlines healthcare back-office processes including billing, claims, and compliance for improved efficiency and accuracy.
Acclara Solutions is a Nashville-based revenue cycle management provider for healthcare organizations. It handles patient billing, insurance claims processing, and denial management, serving over 200 hospitals and physician groups. The firm uses automation to reduce days in accounts receivable and improve collection rates.
Cloudmed is a Nashville-based healthcare revenue integrity firm delivering recovery services to over 400 providers nationwide. With more than 675 engagements completed, it audits claims for accurate reimbursement in inpatient and outpatient settings. Specializing in DRG validation and charge capture, Cloudmed enhances financial performance through technology-driven reviews and compliance expertise.
HQ CountryUnited StatesUnited KingdomUnited StatesUnited States
HQ City
Orlando, FL
London
Houston, TX
Chicago, IL
Deal Date18 Aug 202614 Oct 20256 Dec 202310 Jan 2022
Valuationundisclosedundisclosed$675M$4.1B
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all R1 RCM acquisitions and their M&A valuation multiples.

Start Free Trial

R1 RCM Competitors

R1 RCM competitors include listed companies like Waystar, Craneware, Glaukos and M3 Inc., and private ones like Commure and Doctolib.

Public and private companies comparable to R1 RCM
CompanyHQStatusRevenueEBITDAValuationRevenue Multiple
WaystarUnited StatesUnited StatesPublicly listed$1.1B$390M$5.1B5.2x
CranewareUnited KingdomUnited KingdomPublicly listed$206M$59M$589M2.7x
GlaukosUnited StatesUnited StatesPublicly listed$507M($157M)$9.5B14.6x
M3 Inc.JapanJapanPublicly listed$2.3B$473M$7.7B3.0x
CommureUnited StatesSan Francisco, CAPrivate$200M-$7B35.0x
DoctolibFranceParisPrivate$400M-$6.4B16.0x

R1 RCM Public Comps

R1 RCM is no longer listed, but its public comps include Glaukos, M3 Inc., United Imaging, Pro Medicus, Waystar, Doximity, ICON plc, CCC Intelligent Solutions, Privia Health and Tieto.

Last FYEV/RevenueEV/EBITDA
RevenueEBITDALast FYLTM2027ELast FYLTM2027E
Glaukos$507M($157M)18.4x14.6x(59.6x)166.3x
M3 Inc.$2.3B$473M3.1x3.0x14.8x11.6x
United Imaging$2.1B$367M5.5x4.8x30.7x26.9x
Pro Medicus$186M$147M66.6x62.7x84.4x77.6x
Waystar$1.1B$390M5.8x5.2x16.3x12.3x
Doximity$645M$229M6.3x6.2x17.7x11.9x
ICON plc$8.3B$816M1.9x1.9x19.2x11.3x
CCC Intelligent Solutions$1.1B$238M4.8x4.5x21.5x10.8x

This data is available for Pro users. Sign up to see all R1 RCM competitors and their valuation data.

Start Free Trial

Common questions about R1 RCM

When was R1 RCM founded?R1 RCM was founded in 2003.
Where is R1 RCM headquartered?R1 RCM is headquartered in Chicago, IL, United States.
Is R1 RCM publicly listed?No, R1 RCM was acquired by TowerBrook Capital Partners in August 2024.
Who acquired R1 RCM?R1 RCM was acquired by TowerBrook Capital Partners in August 2024.
How much was R1 RCM acquired for?R1 RCM was acquired for $8.9B in August 2024, a 3.9x revenue multiple.
How much funding has R1 RCM raised?R1 RCM has raised $200M across 1 funding round.
What was R1 RCM's last funding round?R1 RCM's last funding round was a $200M undisclosed-stage round in December 2015, led by TowerBrook Capital Partners and Ascension.
Who are R1 RCM's investors?R1 RCM's investors include Ascension and TowerBrook Capital Partners.
Which companies are comparable to R1 RCM?Companies comparable to R1 RCM include Waystar, Craneware, Glaukos, M3 Inc., Commure and Doctolib.
How many companies has R1 RCM acquired?R1 RCM has acquired 8 companies, including Humata Health, Phare Health, Acclara Solutions, Cloudmed and VisitPay.
What was the largest acquisition by R1 RCM?The $4.1B acquisition of Cloudmed in January 2022 is the largest acquisition R1 RCM has made to date.

See companies similar to R1 RCM

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial